The mission of the Center for Protein Degradation (CPD) at Dana-Farber Cancer Institute is to advance the rational design and development of targeted protein degraders and molecular glues, with the goal of modulating compelling therapeutic targets. CPD's leadership in these areas is supported by collaborations with other laboratories at DFCI, and we receive research funding and operational support from Deerfield Management and its affiliates.
learning is paramount, failure is necessary to succeed, and humility is an asset.
every individual should have the opportunity to provide and solicit feedback, and asking for help is a strength.
in helping others succeed – we celebrate our successes together and recognize the contributions of the team.
in scientific excellence, challenging dogma, and asking “WHY?”.
our research must push scientific boundaries and accelerate the discovery of transformational medicines.
From achieving the first remissions in childhood cancer with chemotherapy in 1948, to developing the very latest new therapies, Dana-Farber Cancer Institute is one of the world's leading centers of cancer research and treatment. It is the only center ranked in the top 4 of U.S. News and World Report's Best Hospitals for both adult and pediatric cancer care.
Deerfield is an investment management firm committed to advancing healthcare through investment, information and philanthropy. The Firm works across the healthcare ecosystem to connect people, capital, ideas and technology in bold, collaborative and inclusive ways. For more information, please visit www.deerfield.com.